









Markets
/
Stocks
/
nasdaq-pvla
/

Palvella Therapeutics Inc

PVLA

82.200USD

+5.770+7.55%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

911.46MMarket Cap

LossP/E TTM



Palvella Therapeutics Inc

82.200

+5.770+7.55%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Palvella Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Palvella Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 77 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 188.62.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Palvella Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

77 / 392

Overall Ranking

198 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Palvella Therapeutics Inc Highlights

StrengthsRisks

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

Undervalued

The company’s latest PE is -32.71, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 9.52M shares, increasing 19.72% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 89.70K shares of this stock.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

188.625

Target Price

+130.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Palvella Therapeutics Inc is 6.80, ranking 211 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.80

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.98

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Palvella Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Palvella Therapeutics Inc is 6.73, ranking 231 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -32.71, which is -99.09% below the recent high of -0.30 and -54.74% above the recent low of -50.62.

Score

Industry at a Glance

Previous score

6.73

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 77/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Palvella Therapeutics Inc is 8.50, ranking 105 out of 392 in the Biotechnology & Medical Research industry. The average price target is 136.50, with a high of 200.00 and a low of 91.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

188.625

Target Price

+130.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Palvella Therapeutics Inc

PVLA

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Palvella Therapeutics Inc is 7.01, ranking 120 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 101.57 and the support level at 67.53, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.71

Change

0.3

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-1.846

Sell

RSI(14)

44.112

Neutral

STOCH(KDJ)(9,3,3)

47.573

Buy

ATR(14)

6.509

High Vlolatility

CCI(14)

-29.752

Neutral

Williams %R

63.721

Sell

TRIX(12,20)

-0.885

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

80.090

Buy

MA10

80.870

Buy

MA20

89.173

Sell

MA50

94.434

Sell

MA100

83.655

Sell

MA200

58.387

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Palvella Therapeutics Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 80.45%, representing a quarter-over-quarter increase of 28.49%. The largest institutional shareholder is The Vanguard, holding a total of 558.76K shares, representing 4.72% of shares outstanding, with 275.75% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Kaupinen (Wesley H.)

1.61M

BVF Partners L.P.

1.16M

+66.71%

Suvretta Capital Management, LLC

822.40K

+15.11%

Frazier Life Sciences Management, L.P.

722.40K

Integrated Finance Group

559.95K

The Vanguard Group, Inc.

Star Investors

494.66K

+201.97%

First Light Asset Management, LLC

541.54K

BlackRock Institutional Trust Company, N.A.

449.40K

+9.68%

Perceptive Advisors LLC

395.09K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Palvella Therapeutics Inc is 4.25, ranking 96 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is -0.16. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Palvella Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.